Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.

Clearance of ctDNA at 6 months was observed in 3/7 (43%) in the observation arm and 1/9 (11%) in the chemotherapy arm (P=0.98). The phase II endpoint was not met; enrollment was halted under prespecified stopping rules based on the original assay. No improvement in clearance was seen after 6 months of chemotherapy in ctDNA-detected resected stage IIA colon cancer. The abstract notes future integral-biomarker trials must account for assay specificity in this population.

ASCO Gastrointestinal Cancers Symposium 2024